1 |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-49. DOI: 10.3322/caac.21660
|
2 |
Chudy-Onwugaje K, Huang WY, Su LJ, et al. Aspirin, ibuprofen, and reduced risk of advanced colorectal adenoma incidence and recurrence and colorectal cancer in the PLCO Cancer Screening Trial[J]. Cancer, 2021, 127(17): 3145-55. DOI: 10.1002/cncr.33623
|
3 |
Shamay-Ramot A, Khermesh K, Porath HT, et al. Fmrp interacts with Adar and regulates RNA editing, synaptic density and locomotor activity in zebrafish[J]. PLoS Genet, 2015, 11(12): e1005702. DOI: 10.1371/journal.pgen.1005702
|
4 |
Shah S, Molinaro G, Liu BT, et al. FMRP control of ribosome translocation promotes chromatin modifications and alternative splicing of neuronal genes linked to autism[J]. Cell Rep, 2020, 30(13): 4459-72.e6. DOI: 10.1016/j.celrep.2020.02.076
|
5 |
Pedini G, Buccarelli M, Bianchi F, et al. FMRP modulates the Wnt signalling pathway in glioblastoma[J]. Cell Death Dis, 2022, 13(8): 719. DOI: 10.1038/s41419-022-05019-w
|
6 |
Lucá R, Averna M, Zalfa F, et al. The fragile X protein binds mRNAs involved in cancer progression and modulates metastasis formation[J]. EMBO Mol Med, 2013, 5(10): 1523-36. DOI: 10.1002/emmm.201302847
|
7 |
Zhao XL, Yang J, Zhang J, et al. Inhibitory effect of aptamer-carbon dot nanomaterial-siRNA complex on the metastasis of hepatocellular carcinoma cells by interfering with FMRP[J]. Eur J Pharm Biopharm, 2022, 174: 47-55. DOI: 10.1016/j.ejpb.2022.03.013
|
8 |
Shen ZF, Liu BW, Wu BT, et al. FMRP regulates STAT3 mRNA localization to cellular protrusions and local translation to promote hepatocellular carcinoma metastasis[J]. Commun Biol, 2021, 4(1): 540. DOI: 10.1038/s42003-021-02071-8
|
9 |
Zeng QQ, Saghafinia S, Chryplewicz A, et al. Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion[J]. Science, 2022, 378(6621): eabl7207. DOI: 10.1126/science.abl7207
|
10 |
Hu YH, Gao QZ, Ma S, et al. FMR1 promotes the progression of colorectal cancer cell by stabilizing EGFR mRNA in an m6A-dependent manner[J]. Cell Death Dis, 2022, 13(11): 941. DOI: 10.1038/s41419-022-05391-7
|
11 |
Di Grazia A, Marafini I, Pedini G, et al. The fragile X mental retardation protein regulates RIPK1 and colorectal cancer resistance to necroptosis[J]. Cell Mol Gastroenterol Hepatol, 2021, 11(2): 639-58. DOI: 10.1016/j.jcmgh.2020.10.009
|
12 |
Lei G, Mao C, Yan YL, et al. Ferroptosis, radiotherapy, and combination therapeutic strategies[J]. Protein Cell, 2021, 12(11): 836-57. DOI: 10.1007/s13238-021-00841-y
|
13 |
McGillicuddy LT, Fromm JA, Hollstein PE, et al. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis[J]. Cancer Cell, 2009, 16(1): 44-54. DOI: 10.1016/j.ccr.2009.05.009
|
14 |
Angius A, Pira G, Scanu AM, et al. MicroRNA-425-5p expression affects BRAF/RAS/MAPK pathways in colorectal cancers[J]. Int J Med Sci, 2019, 16(11): 1480-91. DOI: 10.7150/ijms.35269
|
15 |
Al-Obeed O, El-Obeid AS, Matou-Nasri S, et al. Herbal melanin inhibits colorectal cancer cell proliferation by altering redox balance, inducing apoptosis, and modulating MAPK signaling[J]. Cancer Cell Int, 2020, 20: 126. DOI: 10.1186/s12935-020-01206-x
|
16 |
O’Donnell WT, Warren ST. A decade of molecular studies of fragile X syndrome[J]. Annu Rev Neurosci, 2002, 25: 315-38. DOI: 10.1146/annurev.neuro.25.112701.142909
|
17 |
阳慧芝, 李思锐, 蔡桂月, 等. 脆性X智力低下蛋白在肿瘤致病机制中的研究进展[J]. 皮肤性病诊疗学杂志, 2023, 30(5): 460-4.
|
18 |
Lei G, Zhang YL, Koppula P, et al. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression[J]. Cell Res, 2020, 30(2): 146-62. DOI: 10.1038/s41422-019-0263-3
|
19 |
Yang JW, Mo JJ, Dai JJ, et al. Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer[J]. Cell Death Dis, 2021, 12(11): 1079. DOI: 10.1038/s41419-021-04367-3
|
20 |
He ZK, Yang JB, Sui CY, et al. FAM98A promotes resistance to 5-fluorouracil in colorectal cancer by suppressing ferroptosis[J]. Arch Biochem Biophys, 2022, 722: 109216. DOI: 10.1016/j.abb.2022.109216
|
21 |
Wang R, Xing R, Su Q, et al. Knockdown of SFRS9 inhibits progression of colorectal cancer through triggering ferroptosis mediated by GPX4 reduction[J]. Front Oncol, 2021, 11: 683589. DOI: 10.3389/fonc.2021.683589
|
22 |
Roemhild K, von Maltzahn F, Weiskirchen R, et al. Iron metabolism: pathophysiology and pharmacology[J]. Trends Pharmacol Sci, 2021, 42(8): 640-56. DOI: 10.1016/j.tips.2021.05.001
|
23 |
Liu XF, Hai Y, Dong JQ, et al. Realgar-induced KRAS mutation lung cancer cell death via KRAS/Raf/MAPK mediates ferroptosis[J]. Int J Oncol, 2022, 61(6): 157. DOI: 10.3892/ijo.2022.5447
|
24 |
Sun L, Wang H, Xu D, et al. Lapatinib induces mitochondrial dysfunction to enhance oxidative stress and ferroptosis in doxorubicin-induced cardiomyocytes via inhibition of PI3K/AKT signaling pathway[J]. Bioengineered, 2022, 13(1): 48-60. DOI: 10.1080/21655979.2021.2004980
|
25 |
Soleimani A, Rahmani F, Saeedi N, et al. The potential role of regulatory microRNAs of RAS/MAPK signaling pathway in the pathogenesis of colorectal cancer[J]. J Cell Biochem, 2019, 120(12): 19245-53. DOI: 10.1002/jcb.29268
|
26 |
Vitiello PP, Cardone C, Martini G, et al. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines[J]. J Exp Clin Cancer Res, 2019, 38(1): 41. DOI: 10.1186/s13046-019-1035-0
|
27 |
Hong S, Jeon M, Kwon J, et al. Targeting RAF isoforms and tumor microenvironments in RAS or BRAF mutant colorectal cancers with SJ-C1044 for anti-tumor activity[J]. Curr Issues Mol Biol, 2023, 45(7): 5865-78. DOI: 10.3390/cimb45070371
|
28 |
Casingal CR, Kikkawa T, Inada H, et al. Identification of FMRP target mRNAs in the developmental brain: FMRP might coordinate Ras/MAPK, Wnt/β‑catenin, and mTOR signaling during corticogenesis[J]. Mol Brain, 2020, 13(1): 167. DOI: 10.1186/s13041-020-00706-1
|